NYSE - Delayed Quote USD

Teleflex Incorporated (TFX)

134.65 +0.45 (+0.34%)
At close: 4:00:02 PM EDT
134.65 0.00 (0.00%)
After hours: 5:05:00 PM EDT
Trade TFX on Coinbase
Chart Range Bar
Loading chart for TFX

News headlines Teleflex has received FDA approval for its EZPLAZ Freeze Dried Plasma, marking a significant advancement in blood-component therapy. Additionally, the company will discuss its Q2 earnings on August 6, 2026, amid challenges in revenue growth and cash flow.

Teleflex has received FDA approval for its EZPLAZ Freeze Dried Plasma, marking a significant advancement in blood-component therapy. Additionally, the company will discuss its Q2 earnings on August 6, 2026, amid challenges in revenue growth and cash flow.

Updated 19s ago · Powered by Yahoo Scout
  • Previous Close 134.20
  • Open 134.00
  • Bid 125.58 x 30000
  • Ask 139.76 x 20000
  • Day's Range 131.75 - 135.25
  • 52 Week Range 100.18 - 139.67
  • Volume 483,506
  • Avg. Volume 580,721
  • Market Cap (intraday) 5.961B
  • Beta (5Y Monthly) 0.82
  • PE Ratio (TTM) 2,693.00
  • EPS (TTM) 0.05
  • Earnings Date Aug 6, 2026
  • Forward Dividend & Yield 1.36 (1.01%)
  • Ex-Dividend Date May 22, 2026
  • 1y Target Est 147.45

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

www.teleflex.com

15,500

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 7/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TFX
10.94%
S&P 500 (^GSPC)
6.88%

1-Year Return

TFX
17.93%
S&P 500 (^GSPC)
14.84%

3-Year Return

TFX
45.22%
S&P 500 (^GSPC)
59.66%

5-Year Return

TFX
64.75%
S&P 500 (^GSPC)
65.56%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 548.26M
Earnings -8.15M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-500M
0
500M
 

Analyst Insights

View More

Top Analyst

Raymond James
51/100
Latest Rating
Outperform
 

Analyst Price Targets

135.00
147.45 Average
134.65 Current
160.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 7/28/2026
Analyst UBS
Rating Action Initiated
Rating Neutral
Price Action Announces
Price Target 145
 

Statistics

View More

Valuation Measures

Annual
As of 7/28/2026
  • Market Cap

    5.94B

  • Enterprise Value

    8.32B

  • Trailing P/E

    2.24k

  • Forward P/E

    20.33

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.80

  • Price/Book (mrq)

    1.93

  • Enterprise Value/Revenue

    3.91

  • Enterprise Value/EBITDA

    31.72

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -47.43%

  • Return on Assets (ttm)

    2.33%

  • Return on Equity (ttm)

    0.04%

  • Revenue (ttm)

    2.13B

  • Net Income Avi to Common (ttm)

    1.36M

  • Diluted EPS (ttm)

    0.05

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    333.06M

  • Total Debt/Equity (mrq)

    88.79%

  • Levered Free Cash Flow (ttm)

    -3.68M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

134.65 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

Research Reports

View More
  • Lowering target price to $141.00

    TELEFLEX INC has an Investment Rating of HOLD; a target price of $141.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.

    Rating
    Price Target
     
  • Raising target price to $142.00

    TELEFLEX INC has an Investment Rating of HOLD; a target price of $142.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.

    Rating
    Price Target
     
  • Lowering target price to $137.00

    TELEFLEX INC has an Investment Rating of HOLD; a target price of $137.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.

    Rating
    Price Target
     
  • Raising target price to $140.00

    TELEFLEX INC has an Investment Rating of HOLD; a target price of $140.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.

    Rating
    Price Target
     

People Also Watch